Kornimate/medical-research-clean huggingface dataset:
lactobacillus casei strain shirota fermented milk for alleviating hard stools in vietnam

Conditions: Constipation

Summary: the objective of this study is to provide evidence supporting the efficacy of fermented milk containing lactobacillus casei strain shirota in alleviating hard or lumpy stools. a randomized, controlled trial has been designed on constipated adults with a high prevalence of hard stools in vietnam.


Eligibility criteria:
inclusion criteria: * female or male, aged between 18 to 60 years. * aware of producing hard or lumpy stools (bs score of 1 or 2) frequently. * produce hard or lumpy stools (bs score of 1 or 2) ≥ 25% of bowel movements during 2 weeks of screening period. * voluntarily provide written informed consent to participate in the study. exclusion criteria: * subjects whose constipation symptoms are caused by primary organic disease of the colon or pelvic floora or which, in the investigator's opinion, is caused by medication (e.g. morphine, codeine). * subjects with metabolic disorders, neurological disorders or any significant diseases or concomitant condition (e.g. abdominal/gastrointestinal surgery) that, in the investigator's opinion, would interfere with participation in the study. * subjects with any known allergic reactions to any ingredients of milk. * pregnant or nursing (breast-feeding) women. * subjects who are unable to refrain from or anticipate the use of any medication (including laxatives, diuretics, prescription and non-prescription drugs, vitamins and herbal supplements), except for paracetamol, oral contraceptives, or hormonal replacement therapy from 2-week before the initiation of screening of subject bs score to the end of the study. * subjects who are unable to refrain from or anticipate the use of any probiotics, prebiotics or yogurts from 2-week before the initiation of screening of subject bs score to the end of the study. * participation in another study with investigational product within 2 months prior to this study. * drug or alcohol abuse.
magnetic resonance myocardial stress perfusion in pediatric patients with cardiovascular disease

Conditions: Kawasaki Disease; Cardiovascular Disease; Anomalous Origin of Coronary Artery

Summary: the goal of this observational study is to evaluate myocardial ischemia and myocardial microcirculation dysfunction in children with cardiovascular disease by myocardial stress perfusion imaging. during their disease progress, participants will undergo myocardial stress perfusion, laboratory tests when hospitalization and follow-up, and the baseline data will be collected in the admission. all the above examination data will be analysed to identify early subclinical myocardial changes and evaluate the value of magnetic resonance myocardial stress perfusion in predicting prognosis.


Eligibility criteria:
inclusion criteria: * patients diagnosed with cardiovascular disease, including kawasaki disease, anomalous origin of coronary artery, postoperative congenital heart disease. exclusion criteria: * mental abnormalities or poor compliance ; heart, kidney and other important organs were seriously incomplete. * mri examination contraindications ; gadolinium contrast agent contraindications ; claustrophobia.
the hep-oks study - hemifield eye patching and optokinetic stimulation to treat hemispatial neglect in stroke patients

Conditions: Spatial Neglect; Cerebral Stroke

Summary: spatial neglect represents one of the major cognitive disorders following stroke. patients patients fail to be aware of objects or people to their left and orientate instead to their right side. enduring neglect has been found to be a poor prognostic indicator for functional independence following stroke. despite some promising experimental accounts there are no established treatments for this condition. the aim of this study is to test whether a combined treatment with hemifield eye patching (hep) and optokinetic stimulation (oks) can permanently reduce neglect behaviour and improve functional outcome in patients with hemispatial neglect following stroke. the investigators hypothesise that the treatment with hep and oks will lead to a greater reduction of neglect scoring in the neglect test battery as well as a greater improvement in functional independence scores as compared to the spontaneous clinical course of the usual-care control group.

to specify, this study should answer the following main question: does the daily wearing of hemifield eye patches over a period of 1 week in combination with daily sessions of optokinetic stimulation lead to a significant reduction of neglect behaviour as measured by total scores in a paper-and-pencil neglect test battery and/or an improvement in functional independence scores (catherine-bergego-scale, barthel index) in a cohort of stroke patients with acute hemispatial neglect as compared to the spontaneous course of the disease in a control patient group without a neglect-specific treatment?

Eligibility criteria:
inclusion criteria: * right hemisphere stroke * spatial neglect as determined by pathological scores in at least two tests of a neglect test battery (azouvi et al., jnnp, 2004) * age \> 18 years old * informed consent signature exclusion criteria: * bilateral or previous unilateral stroke lesions * pre-existing neurodegenerative disease * inability to give informed consent
collection of blood for gene expression/genomic studies in individuals with diabetes (qatar)

Conditions: Diabetes Mellitus; Type 2 Diabetes Mellitus

Summary: this protocol is designed to gather a small amount of blood for extraction of dna for the study of the genetic basis of diabetes. the study population will include individuals with known diabetes, and controls without diabetes. investigators aim to understand the genetics of diabetes, and will use the cells and serum from this blood to perform genotyping and gene expression studies of individuals with diabetes and relevant controls.

this protocol is designed to collect a small amount of blood for extraction of dna (genetic material) for the study of the genetic basis of diabetes. the study population will include individuals with known diabetes and controls without diabetes. additionally, this protocol will recruit individuals from the following locations: the qatar diabetes association, the governmental ministries of qatar, and subjects who have participated in dr. bener's hmc protocol #231 entitled "a preliminary study of genetic pre-disposition to diabetic mellitus in the state of qatar." individuals with diabetes may also be recruited from the hamad hospital outpatient adult diabetes clinics (there are eight diabetes clinics each week) and/or from the population of subjects who previously participated in dr. mushlin's irb approved protocol #0608008703 entitled "comparing the clinical management and genetic markers of diabetes in qatar to international standards" at hamad medical corporation or irb approved protocol #0602008388 entitled "the impact of cardiac and genetic risk factors on acute myocardial infarction and cerebrovascular stroke in qatar: a case-control study". in this protocol, researchers will survey medical records of patients with diabetes, in order to study the clinical characteristics of these individuals, and the researchers will collect blood to evaluate the genetic characteristics of individuals with diabetes. the researchers will also collect blood samples of individuals without diabetes to serve as control.

Eligibility criteria:
diabetes group inclusion criteria: * must provide informed consent * males and females, age 18 years and older * documented evidence of diabetes using at least one of the following: (1) blood tests consistent with type-ii diabetes; (2) oral glucose tolerance tests consistent with type-ii diabetes; (3) subject taking medication to treat type-ii diabetes. exclusion criteria: * individual refuses consent * pregnant females with gestational diabetes * type-i diabetes normal control group inclusion criteria: * must provide informed consent * males or females ages 18 years and older * resolved gestational diabetes exclusion criteria: * individual refuses consent. * individuals with history of diabetes.

Keywords: diabetes mellitus diabetes type-2 adult onset
risk factors for postpartum hemorrhage in patients with histologically verified placenta accreta

Conditions: Postpartum Hemorrhage (PPH); Placental Dysfunction

Summary: this retrospective, monocentric study aims to examine risk factors for postpartum hemorrhage in women with histologically verified placenta accreta. women with histologically verified placenta accreta are divided into two groups: women with normal blood loss (bv \< 500 ml) versus women with increased blood loss (bv ≥ 500 ml). the clinical data of pregnant women with histologically verified placental disorders, who gave birth in the women's clinic university hospital basel (usb) between 1986 and 2019, are compared with each other.

placental disorders are defined as abnormal implantation of the placenta due to a defect in the basal decidua. depending on the severity of the incorrect implantation, three different stages can be distinguished (placenta accreta, increta and percreta). placentation disorders are reported in the literature with an increasing frequency of up to 3%. in the last 10 years, the incidence has increased 10-fold and currently affects 1 to 80 out of 2500 births, depending on the literature. not every histologically verified placental disorder is associated with postpartum hemorrhage. according to the world health organization (who), postpartum hemorrhage (pph) is defined as blood loss ≥ 500 ml within 24 hours after delivery. this retrospective, monocentric study aims to examine risk factors for postpartum hemorrhage in women with histologically verified placenta accreta. women with histologically verified placenta accreta are divided into two groups: women with normal blood loss (bv \< 500 ml) versus women with increased blood loss (bv ≥ 500 ml). the clinical data of pregnant women with histologically verified placental disorders, who gave birth in the women's clinic usb between 1986 and 2019, are compared with each other.

Eligibility criteria:
inclusion criteria: * pregnant women with a histologically verified placental disorder who gave birth at the women's hospital usb between 1986 and 2019 exclusion criteria: * existence of a documented refusal

Keywords: placenta histology placenta accreta placenta increta placenta percreta
fixation methods of basicervical fractures

Conditions: Hip Fractures; Osteoporotic Fractures

Summary: this prospective, randomized study included patients aged over 65 years with basicervical fracture of femur from january 2016 to january 2018. the permuted block randomization method was used to randomize participants into groups. the patients were allocated to one of two groups treated via cephalomedullary nail (cmn) or sliding hip screw (shs). functional and radiological evaluations was included the mobility score, harris hip score, modified barthel index, the singh index, the tip-apex distance, and fracture settling.

approval for this prospective randomized study was granted by the local ethics review board and all procedures were performed in accordance with the ethical standards of the declaration of helsinki (1964). patients with a basicervical femur fracture were identified on admission to the emergency department of our tertiary hospital from january 2016 to january 2018. patients with scheduled surgery who met the inclusion criteria and provided written informed consent were included in the study. patients were randomly allocated to a study group by permuted blocks of randomly mixed sizes and stratification according to the type of surgery (cmn or shs). randomization was applied using pre-prepared randomization cards, which were placed in opaque sealed envelopes and given to the surgeons to open just prior to surgery, and the designated procedure was then performed.

Eligibility criteria:
inclusion criteria: * basicervical fracture, * age of ≥65 year, * an isolated fracture, * the ability to walk independently (with or without an aid) prior to fracture, * a fracture that had occurred less than one week prior to admission. exclusion criteria: * history of ipsilateral femoral fracture, * a fracture due to malignancy, * limited life expectancy due to medical comorbidities, * any contraindication to surgery, * diagnosed dementia, * any other traumatic fracture on admission.

Keywords: basicervical cervicobasiler hip fracture prospective randomized
pilot study to evaluate 18f-fluorodeoxyglucose (fdg) positron emission tomography /computed tomography (pet/ct) in prediction of early response to chemotherapy in ovarian cancer.

Conditions: Ovarian Cancer

Summary: we hypothesize that 18fdg positron emission tomography (fdg pet) imaging, carried out after the first cycle of chemotherapy, will identify responders, thus permitting early termination of potential toxic therapy in non- responders leading to a significant decrease in morbidity and cost. the value of pet imaging as an early predictor of response to chemotherapy has been shown in other cancers.


Eligibility criteria:
inclusion criteria: * histologically proven ovarian cancer at diagnosis of any stage. * patients with evidence of disease that is radiographically measurable (ct scan) * patients have planned to undergo standard chemotherapy. dose and schedule will be determined per treating physician exclusion criteria: * patients with any other malignancy active within 5 years except for non-melanoma skin cancer, or carcinoma in situ of the cervix. * patients with an active infection * patients of childbearing potential are excluded from this study. * patients who have expected survival \< 3 months. * patients not planning or able to receive the outlined chemotherapy regimen as part of standard practice. * patient unable to complete study

Keywords: ovarian cancer pet ct 04-064
intramural needle ablation for ablation of recurrent ventricular tachycardia

Conditions: Ventricular Tachycardia

Summary: the purpose of the study is to assess the effectiveness and safety of a new device called an intramural needle ablation catheter (ina catheter). the ina catheter is used for locating and ablating ventricular arrhythmias that have failed standard radiofrequency ablation. this approach is desirable because some people have ventricular arrhythmias that originate deep within the heart muscle where it is not abolished by ablation with standard catheters. the investigators seek to determine whether the ina catheter can potentially help people who have ventricular arrhythmias that have failed standard radiofrequency ablation. the investigators also want to determine if it is likely to be safe, without excessive side effects.


Eligibility criteria:
inclusion criteria: monomorphic ventricular tachycardia (vt) or incessant ventricular arrhythmia (defined as \>20% of beats due to ventricular arrhythmia including unifocal premature ventricular contractions (pvcs ), couplets, nonsustained vt) that is causing a decline in left ventricular (lv) ejection fraction to less than 0.50. arrhythmia meets the following criteria: 1. ventricular arrhythmia is recurrent and symptomatic 2. prior antiarrhythmic drug therapy has failed due to recurrent ventricular arrhythmia, toxicity, or intolerance * age 18 or older * left ventricular (lv) ejection fraction \> 0.10 as estimated by echocardiography or contrast ventriculography within the previous 90 days * failed prior vt or pvc ablation due to spontaneous recurrence of the arrhythmia or frequent pvcs. * able and willing to comply with all pre-, post-, and follow-up testing and requirements * signed informed consent exclusion criteria: * patients with idiopathic vt defined as vt that originates from a region without evidence of scar detected by mri or voltage mapping in a patient without other evidence of heart disease that is not causing significant depression of ventricular function. * definite protruding left ventricular thrombus on pre-ablation echocardiography when lv ablation is required. * thrombotic myocardial infarction within the preceding two (2) months. * other disease process that is likely to limit survival to less than 12 months. * class iv heart failure, unless heart failure is due to frequent or incessant vt. * contraindication to heparin. * allergy to radiographic contrast dye. * severe aortic stenosis * severe mitral regurgitation with a flail mitral valve leaflet. * significant congenital anomaly or medical problem that in the opinion of the principal investigator would preclude enrollment into the study. * enrolled in another investigational study evaluating a drug or device. * unstable angina that is not due to frequent or incessant vt. * women who are pregnant. * thrombocytopenia (platelet count \< 50,000) or coagulopathy. * acute non-cardiovascular illness or systemic infection. * cardiogenic shock unless it is due to incessant vt

Keywords: ventricular tachycardia ablation ventricular arrhythmia
vasq external support for arteriovenous fistula

Conditions: Arterio-Venous Fistula; ESRD; Steal Syndrome; Aneurysm; Renal Failure; Renal Disease; Diabetes Mellitus; Kidney Failure

Summary: this is a prospective clinical study of the vasq external support for arteriovenous fistulas. the device is designed to improve fistula outcomes by optimizing the geometrical configuration of the fistula, influencing hemodynamics, minimizing turbulence and promote laminar flow. all patients will be implanted with the vasq device and will be followed up for a duration of 24 months.


Eligibility criteria:
inclusion criteria: 1. main study cohort: patients referred for creation of a new brachiocephalic fistula who consent to take part in the study and which are not indicated for a more distal fistula per treatment guidelines. supplementary study cohort: patients referred for creation of a new forearm fistula who consent to take part in the study. 2. male and female participants. 3. age 18-80 years. 4. patients willing and able to attend follow up visits over a period of 24 months. exclusion criteria: 1. patients with the planned index procedure being a revision surgery of an existing fistula. 2. main study cohort: target artery smaller than 2.5 mm or larger than 6 mm in inner diameter by preoperative ultrasound. supplementary study cohort: target artery smaller than 2 mm or larger than 4.1 mm in inner diameter by preoperative ultrasound. 3. main study cohort: target vein smaller than 2.5 mm in inner diameter by preoperative ultrasound. supplementary study cohort: target vein smaller than 2 mm in inner diameter by preoperative ultrasound. 4. significantly stenotic target vein on the side of surgery (≥50%) as diagnosed on preoperative ultrasound. (scan should include the area between the planned anastomosis site and the axillary vein.) 5. unusual anatomy or vessel dimensions (observed on pre-operative ultrasound or intraoperatively) and which preclude adequate fit of the vasq. 6. patients with central venous stenosis or obstruction on the side of surgery. 7. depth of vein greater than 8 mm (on ultrasound) on side of surgery. 8. known coagulation disorder. 9. congestive heart failure nyha class ≥ 3. 10. prior steal on the side of surgery. 11. known allergy to nitinol. 12. life expectancy less than 30 months. 13. patients expecting to undergo kidney transplant within 6 months of enrollment. 14. women of child bearing age without documented current negative pregnancy test. 15. inability to give consent and/or comply with the study follow up schedule.
a study of aripiprazole (abilify) in patients with bipolar mania

Conditions: Bipolar Disorder

Summary: the purpose of this clinical research study is to learn if outpatients with bipolar mania who are partially nonresponsive to lithium or valproate monotherapy can achieve stable symptoms on a combination treatment of aripiprazole plus lithium or valproate.


Eligibility criteria:
inclusion criteria: * men and women \> or = to 18 years of age meeting diagnostic and statistical manual for mental disorders, fourth edition, text revision (dsm-iv-tr) criteria for bipolar i disorder, currently experiencing a manic or mixed episode with a history of one or more manic or mixed episodes or sufficient severity to require hospitalization and/or treatment with a mood stabilizer or antipsychotic.

Keywords: bipolar i disorder with a recent manic or mixed episode
effect of eriocitrin supplementation in subjects with intermediate hyperglycemia

Conditions: Pre Diabetes

Summary: first, it will be evaluated whether supplementation of eriocitrin reduces hyperglycemia and insulin resistance, significantly reducing the risk of diabetes. the effects of eriocitrin on the lipid profile, inflammatory, endothelial, hepatic and renal biomarkers will also be evaluated. it is expected that metabolic parameters that constitute risk factors for diabetes and associated chronic diseases are expected to be improved by supplementation with eriocitrin

volunteers will be invited to appear in a 12-hour fast to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview to confirm eligibility according to the inclusion and exclusion criteria. the collection of blood and the glycemic curves will be carried out next to a laboratory of clinical analyzes, commercial, based in the city of araraquara. the sample number took into account variances on glycated hemoglobin with a type i error α = 0.05 and a type ii error β = 0.2 (80% power) (mohammad, 2015). the minimum sample size considering an approximately 20% dropout rate, should have 20 individuals per group. in order to ensure adequate nutrition for the nutritional and energetic needs of volunteers, an individual food plan shall be prescribed, calculated according to the dri equations. the volunteer will be asked to complete the food record for three days at the 3rd, 5th, 7th, 9th and 11th week. data analysis of energy intake, macronutrients and micronutrients will be performed through the dietbox® . the anthropometric measurements will be performed before the intervention and in the 3rd, 5th, 7th, 9th and 11th week by nutritionist. four samples of 30ml of fasting blood each will be obtained before the intervention, in the 4th, 8th and 12th week in the laboratory of clinical analyzes. the blood will be centrifuged to obtain the serum, which will be frozen at -80 ° c until subsequent biochemical analyzes. normality and homogeneity will be evaluated by shapiro-wilk test and levine tests, respectively. the t test will be used to compare baseline time between groups. the two-way repeated-measures anova will be used to compare changes within and between the eriocitrin and control groups over the 12-week period. p significant at ≤ 0.05.

Eligibility criteria:
inclusion criteria: * glycemia of 6.1 to 7.0 mmol / l * glycated hemoglobin with values between 5.7 and 6.4% exclusion criteria: * use of drugs, vitamins and dietary supplements, alcohol consumption (\> 20 g alcohol/d), and intense physical activity (\> 5 hours/week). * history of cardiovascular disease, diabetes mellitus, liver or kidney disease

Keywords: eriocitrin intermediate hyperglycemia citrus bioflavonoids